logo-loader

SCYNEXIS reveals positive interim data from its Phase 3 FURI study

Published: 17:42 11 Feb 2019 EST

SCYNEXIS, Inc. (NASDAQ:SCYX) President & CEO Dr. Marco Taglietti sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The biotechnology company's lead product candidate is ibrexafungerp (formerly known as SCY-078), an IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

3 minutes ago